Agios Pharmaceuticals

Traded on the St. Petersburg Stock Exchange
Agios Pharmaceuticals is a public American pharmaceutical company focused on developing small-molecule anti-cancer therapeutics targeting cancer cell metabolism via the growth factor pathway. Agios is a Delaware corporation headquartered in Cambridge, Massachusetts.
Agios Pharmaceuticals stock price chart
vol.
change
P/E
Net profit
P/B
Book value
P/FCF
FCF
Yield
Growth potential

Agios Pharmaceuticals balance sheet

Report period2017 2018 2019 2020 2021 2022
End date of the reporting period
Capitalization, $
Capitalization, $
Enterprise Value
Book Value
Shareholders Book Value
Current liabilities
Noncurrent liabilities
Total liabilities
Debt
Cash and cash equivalents
Net debt
Assets
Total ordinary shares
Ordinary share price

Agios Pharmaceuticals cash flows

Report period2017 2018 2019 2020 2021 2022
End date of the reporting period
Sales
Gross profit
Operation Income
Earnings
Shareholders earnings
EBITDA
Operation Cashflow
Capital expenditure
Free Cash Flow
EPS

Agios Pharmaceuticals multipliers

Report period2017 2018 2019 2020 2021 2022
P/E
E/P
P/B
P/S
P/FCF
L/A
Debt-To-Equity
Net Debt/EBITDA
EV/EBITDA

Agios Pharmaceuticals profitability

Report period2017 2018 2019 2020 2021 2022
ROA
ROE
ROS
Gross margin
EBITDA Margin
Operating margin
Agios Pharmaceuticals assets
Agios Pharmaceuticals cash flows

Agios Pharmaceuticals shares

TickerNameTypeNominal valueISINPrice
AGIO:USAgios Pharmaceuticals, Inc.Common share-US00847X1046$29.53
Agios Pharmaceuticals news
05.05.2022
Agios Pharmaceuticals' GAAP loss for 3 months of 2022 was $0.095 billion, compared to a profit of $1.874 billion in the previous year. Revenues amounted to $832 thousand. The company did not receive revenues a year earlier.
Source: {source} pictogram investor.agios.com
Pictogram next
24.02.2022
Agios Pharmaceuticals' GAAP net income for 2021 was $1.605 billion, compared with a loss of $0.327 billion in the previous year.
Source: {source} pictogram investor.agios.com
Pictogram next
18.02.2022
Agios Pharmaceuticals has received FDA approval for Pyrukynd. The drug is intended to treat hemolytic anemia in adults with pyruvate kinase deficiency. Pyrukynd will go on sale in the U.S. in two weeks.
Source: {source} pictogram investor.agios.com
Pictogram next
03.11.2021
Agios Pharmaceuticals' GAAP net income for 9M 2021 was $1.699 billion, against a loss of $0.23 billion in the previous year.
Source: {source} pictogram investor.agios.com
Pictogram next
All Agios Pharmaceuticals news
General information
Company nameAgios Pharmaceuticals
Tags#biotechnology
SectorHealth Care / Pharmaceuticals, Biotechnology & Life Sciences / Biotechnology / Biotechnology
Business address88 SIDNEY STREET CAMBRIDGE MA 02139 617-649-8600
Mailing address88 SIDNEY STREET CAMBRIDGE MA 02139
Websitewww.agios.com
Information disclosurewww.sec.gov